HAEMONETICS MCS APHERESIS SYSTEM PROMOTION FOR UNAPPROVED USE
This article was originally published in The Gray Sheet
Executive Summary
HAEMONETICS MCS APHERESIS SYSTEM PROMOTION FOR UNAPPROVED USE is cited in a March 16 warning letter to the firm. The MCS mobile collection apheresis system, which is 510(k) cleared for platelet apheresis, is being promoted "for purposes for which it was never officially cleared and/or approved in violation of the Food, Drug and Cosmetic Act," FDA alleges. "Continued promotion, either written or verbal, could result in regulatory action without further notice," FDA warns.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.